An observational study in Genetic and Inflammatory Polyneuropathies, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 26 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To describe the clinical, electrophysiological, and genetic characteristics of patients with genetic and inflammatory polyneuropathies in France.
To describe the clinical, electrophysiological, and genetic characteristics of genetic and inflammatory peripheral neuropathies in detail in order to advance our understanding of these rare and disabling diseases. This detailed description is also necessary with a view to the future use of innovative treatments. In recent years, there have indeed been spectacular advances in the field of genetic therapies (siRNA, antisense oligonucleotides, gene therapy) and next-generation immunosuppressive therapies (complement inhibitors, anti-FcRN), all of which are applicable in the short- to medium-term for genetic and inflammatory polyneuropathies.
This is a multicenter, prospective-retrospective study using data collected as part of routine clinical care.The objectives are as follows:
73 studies on the registry are indexed under Neuritis; 20 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 123 across 20 observational studies indexed under Neuritis.
Browse Neuritis studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults diagnosed with genetic or inflammatory polyneuropathy and followed in participating neurology centers in France.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Patient opposition to the use of their routine care data for research purposes.
Number and percentage of participants by type of polyneuropathy
Participants will be classified as having genetic or inflammatory polyneuropathy according to the diagnosis documented in their medical records. The number and percentage of participants in each category will be reported.
Time frame: At inclusion, based on the diagnosis documented in the medical record.
Number and percentage of participants by polyneuropathy subtype
The number and percentage of participants in each genetic or inflammatory polyneuropathy subtype, as documented in the medical records, will be reported.
Time frame: At inclusion, based on the diagnosis documented in the medical record.
Demographic characteristics of patients
Description of demographic characteristics of patients with genetic or inflammatory polyneuropathies, including age, sex and other available demographic data.
Time frame: At baseline, corresponding to the date of inclusion in the study, using data available in the medical record up to that date.
Geographical distribution of patients
Description of the geographical distribution of patients with genetic or inflammatory polyneuropathies included in participating centers in France.
Time frame: At baseline, corresponding to the date of inclusion in the study, using data available in the medical record up to that date.
Number and percentage of participants by electrophysiological neuropathy pattern
The electrophysiological neuropathy pattern documented in the medical record will be classified as axonal, demyelinating or mixed. The number and percentage of participants in each category will be reported.
Time frame: At inclusion, based on electrophysiological examinations available in the medical record.
Genetic abnormalities
Description of genetic abnormalities identified in patients with genetic or inflammatory polyneuropathies, when genetic analysis results are available in the medical records.
Time frame: At baseline, corresponding to the date of inclusion in the study, using genetic data available in the medical record up to that date.
Start is estimated for Nov 2026; primary completion for Nov 2036, 120 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →